Canada markets closed

Insmed Incorporated (INSM)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
26.15-0.67 (-2.50%)
At close: 04:00PM EDT
26.15 0.00 (0.00%)
After hours: 04:03PM EDT
Full screen
Trade prices are not sourced from all markets
Previous Close26.82
Open27.09
Bid26.14 x 400
Ask26.18 x 400
Day's Range26.11 - 26.97
52 Week Range17.36 - 32.00
Volume1,960,059
Avg. Volume1,637,945
Market Cap3.885B
Beta (5Y Monthly)0.92
PE Ratio (TTM)N/A
EPS (TTM)-5.34
Earnings DateMay 02, 2024 - May 06, 2024
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est43.87
  • Insider Monkey

    What Makes Insmed (INSM) a Lucrative Investment?

    ClearBridge Investments, an investment management company, released its “ClearBridge Small Cap Growth Strategy” first quarter 2024 investor letter. A copy of the letter can be downloaded here. The Strategy underperformed the benchmark in the quarter. The small-cap growth universe revealed a stark dichotomy despite the positive performance of the benchmark Russell 2000 Growth Index, which […]

  • PR Newswire

    Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

    Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced the granting of inducement awards to seven new employees. In accordance with NASDAQ Listing Rule 5635(c)(4), the awards were approved by Insmed's Compensation Committee and made as a material inducement to each employee's entry into employment with the Company.

  • PR Newswire

    Insmed to Present New Data from Across its Respiratory Portfolio at the American Thoracic Society 2024 International Conference

    Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that it will present nine abstracts from across its respiratory portfolio at the American Thoracic Society (ATS) 2024 International Conference, taking place May 17-22, 2024, in San Diego. Presentations will include late-breaking microbiologic data from the ARISE study of ARIKAYCE® (amikacin liposome inhalation suspension) in patien